POINT Biopharma Global Inc Ordinary Shares | - | 2.39% | - | - | 0 |
Mirati Therapeutics Inc | - | 2.30% | - | - | 0 |
Rain Oncology Inc | - | 1.70% | - | - | 0 |
HUTCHMED (China) Ltd ADR | - | 1.57% | - | - | 0 |
Nuvalent Inc Class A | - | 1.47% | - | - | 0 |
MRSN | 1.46% | 0.343 | -0.29% | 0 | |
Zymeworks Inc Registered Shs | - | 1.44% | - | - | 0 |
Y-mAbs Therapeutics Inc | - | 1.44% | - | - | 0 |
Macrogenics Inc | - | 1.42% | - | - | 0 |
SGEN | 1.41% | 228.74 | 0.00% | 0 |
As of October 20, 2023, ETF Series Solutions - Loncar China BioPharma ETF has been acquired by ETF Series Solutions - Range Cancer Therapeutics ETF. ?ETF Series Solutions - Loncar China BioPharma ETF is an exchange traded fund launched by ETF Series Solutions. The fund is co-managed by Exchange Traded Concepts, LLC. The fund invests in public equity markets of China. The fund invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the Loncar China BioPharma Index, by using full replication technique. ETF Series Solutions - Loncar China BioPharma ETF was formed on August 14, 2018 and is domiciled in the United States.